Cushman William C, Ford Charles E, Cutler Jeffrey A, Margolis Karen L, Davis Barry R, Grimm Richard H, Black Henry R, Hamilton Bruce P, Holland Joanne, Nwachuku Chuke, Papademetriou Vasilios, Probstfield Jeffery, Wright Jackson T, Alderman Michael H, Weiss Robert J, Piller Linda, Bettencourt Judy, Walsh Sandra M
J Clin Hypertens (Greenwich). 2002 Nov-Dec;4(6):393-404. doi: 10.1111/j.1524-6175.2002.02045.x.
Blood pressure control (<140/90 mm Hg) rates for hypertension fall far short of the US national goal of 50% or more. Achievable control rates in varied practice settings and geographic regions and factors that predict improved blood pressure control are not well identified.
To determine the success and predictors of blood pressure control in a large hypertension trial involving a multiethnic population in diverse practice settings.
The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial is a randomized, double-blind, active-controlled clinical trial with a mean follow-up of 4.9 years. Participant enrollment began in February 1994 and follow-up was completed in March 2002.
A total of 623 centers in the United States, Canada, and the Caribbean.
A total of 33,357 participants (aged > or =55 years) with hypertension and at least one other coronary heart disease risk factor.
Participants were randomly assigned to receive (double-blind) chlorthalidone, 12.5-25 mg/d (n=15,255), amlodipine 2.5-10 mg/d (n=9048), or lisinopril 10-40 mg/d (n=9054) after other medication was discontinued. Doses were increased within these ranges and additional drugs from other classes were added as needed to achieve blood pressure control (<140/90 mm Hg).
The outcome measures for this report are systolic and diastolic blood pressure, the proportion of participants achieving blood pressure control (<140/90 mm Hg), and the number of drugs required to achieve control in all three groups combined.
Mean age was 67 years, 47% were women, 35% black, 36% diabetic; 90% were on antihypertensive drug treatment at entry. At the first of two pre-randomization visits, blood pressure was <140/90 mm Hg in only 27.4% of participants. After 5 years of follow-up, the percent controlled improved to 66%. Systolic blood pressure was <140 mm Hg in 67% of participants, diastolic blood pressure was <90 mm Hg in 92%, the mean number of drugs prescribed was 2.0+/-1.0, and the percent on > or =2 drugs was 63%. Blood pressure control varied by geographic regions, practice settings, and demographic and clinical characteristics of participants.
These data demonstrate that blood pressure may be controlled in two thirds of a multiethnic hypertensive population in diverse practice settings. Systolic blood pressure is more difficult to control than diastolic blood pressure, and at least two antihypertensive medications are required for most patients to achieve blood pressure control. It is likely that the majority of people with hypertension could achieve a blood pressure <140/90 mm Hg with the antihypertensive medications available today.
高血压患者的血压控制率(<140/90 mmHg)远低于美国50%及以上的国家目标。不同实践环境和地理区域中可实现的控制率以及预测血压控制改善的因素尚未得到很好的确定。
在一项涉及不同实践环境中多民族人群的大型高血压试验中确定血压控制的成功率和预测因素。
降压和降脂治疗预防心脏病发作试验是一项随机、双盲、活性药物对照的临床试验,平均随访4.9年。参与者招募于1994年2月开始,随访于2002年3月完成。
美国、加拿大和加勒比地区的623个中心。
共有33357名参与者(年龄≥55岁)患有高血压且至少有一项其他冠心病危险因素。
在停用其他药物后,参与者被随机分配接受(双盲)氯噻酮,12.5 - 25 mg/天(n = 15255)、氨氯地平2.5 - 10 mg/天(n = 9048)或赖诺普利10 - 40 mg/天(n = 9054)。在这些范围内增加剂量,并根据需要添加其他类别的额外药物以实现血压控制(<140/90 mmHg)。
本报告的结局指标为收缩压和舒张压、实现血压控制(<140/90 mmHg)的参与者比例以及三组合并后实现控制所需的药物数量。
平均年龄为67岁,47%为女性,35%为黑人,36%患有糖尿病;入组时90%正在接受降压药物治疗。在随机分组前的两次访视中的第一次,只有27.4%的参与者血压<140/90 mmHg。经过5年随访,控制率提高到66%。67%的参与者收缩压<140 mmHg,92%的参与者舒张压<90 mmHg,平均开具的药物数量为2.0±1.